TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
22 hedge funds and large institutions have $21.1M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 7 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
29% less funds holding
Funds holding: 31 → 22 (-9)
30% less capital invested
Capital invested by funds: $30.3M → $21.1M (-$9.21M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$188K |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$154K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$112K |
| 4 |
Renaissance Technologies
New York
|
+$102K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$69.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$1.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$448K |
| 3 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$305K |
| 4 |
QF
QVT Financial
New York
|
-$187K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$82K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
26
TFS Capital
West Chester,
Pennsylvania
| – | -$82K | -84 | Closed |
|
27
Bank of New York Mellon
New York
| – | -$64K | -65 | Closed |
|
|
NC
28
Nexthera Capital
New York
| – | -$62K | -64 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$9K | -9 | Closed |
|
TCON Hedge Fund Activity: Q1 2017 in Review
22 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2017, worth a combined $21.1M — down 30% from $30.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TCON and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was BlackRock, opening a new position worth an estimated $188K. The largest seller was AWM Investment Company, exiting entirely with an estimated $1.1M sold.
- 22 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2017, down from 31 in Q4 2016.
- Funds reported $21.1M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2017, down 30% quarter-over-quarter.
- 4 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2017 and 7 closed out, a net change of -3 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $188K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2017 was AWM Investment Company, an estimated $1.1M sold.
Based on aggregated 13F filings for Q1 2017.